Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alnylam Replaces Sanofi Partnership With Second Regeneron Tie-Up For RNAi Drugs

Apr 08 2019

• By Joseph Haas

Business partners hands on top of each other symbolizing companionship

Related Content

Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro

Aug 11 2018

Regeneron's Less Frequent Eylea Dosing Makes Late Sprint Across FDA Finish Line

Aug 17 2018

Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea

Apr 02 2019

Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs

Mar 22 2018

Related Companies

Alnylam Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

Allergan plc

Roche Holding AG

Novartis AG

Additional Topics

Commercial Deals Business Strategies BioPharmaceutical Neurology Ophthalmic Liver & Hepatic

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window